The Centre Hospitalier Universitaire Vaudois (CHUV), the European Laboratory for Particle Physics (CERN) and THERYQ (ALCEN Group) have entered a deal for the development of an advanced FLASH radiotherapy device.
Based on CERN technology, the device will use very high-energy electron (VHEE) radiation for the treatment of cancers that are resistant to conventional treatments.
It would reduce side effects while increasing effectiveness on tumours by reducing irradiation to a few milliseconds.
The tripartite deal includes planning, development, regulatory compliance, and construction of the radiotherapy device using the FLASH technique.
THERYQ, a part of ALCEN’s healthcare division, will manufacture the device, which will include a compact linear accelerator based on CERN technology.
The company’s FLASHDEEP tool will use VHEE beams of 100MeV to 200MeV by integrating CERN’s innovative compact linear accelerator technology.
This will allow the new FLASH radiotherapy device to treat all types of cancers up to a depth of 20cm.
Claimed to be the world’s first radiotherapy device, the FLASH radiotherapy device is expected to be operational within two years, with the first clinical trials planned for 2025.
Upon completion, the device will be installed at CHUV.
CHUV director-general Philippe Eckert said: “As a university hospital, the CHUV is fully committed to research. FLASH therapy embodies the spirit of innovation that drives us in this field.
“Eager to offer the most effective techniques to patients, we have joined forces with a world-class research centre and a cutting-edge industrial partner to solve a medical, physical and technical problem and find innovative solutions to fight cancer.”